Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Post Menopausal Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abstract
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Drugs In Development, 2022, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.
Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 20, 4, 10, 3, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis - Overview
Post Menopausal Osteoporosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Post Menopausal Osteoporosis - Drug Profiles
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT
Jun 17, 2022: Voluntary announcement - First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China
Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS
Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System
Dec 23, 2021: Radius announces update on TYMLOS (abaloparatide) label
Dec 08, 2021: Radius announces results from the wearABLe trial evaluating abaloparatide transdermal system in postmenopausal women with osteoporosis
Oct 06, 2021: Entera Bio presents positive phase 2 6-month bone mineral density data for oral PTH formulation at Late Breaker ASBMR Conference Session
Sep 22, 2021: Radius Health announces TYMLOS label and business update
Sep 01, 2021: Entera Bio selected for late breaking oral presentation of phase 2 6-month osteoporosis data at ASBMR 2021 Annual Meeting
Jan 25, 2021: Luye Pharma LY06006 completed the last dosing for all subjects in phase III Clinical in China
Dec 14, 2020: Samsung Bioepis initiates phase 3 clinical trial for SB16, proposed biosimilar to Prolia (Denosumab)
Oct 23, 2020: Boan Biotech receives EU clinical trials application approval for Denosumab injection
Sep 09, 2020: Radius Health announces scientific presentations on abaloparatide at ASBMR 2020 Annual Meeting
Sep 08, 2020: Radius Health: Enrollment completed for Phase 3 wearABLe trial
Aug 20, 2020: Entera Bio announces interim data from phase 2 clinical trial of EB613 in osteoporosis and second quarter 2020 financial results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Post Menopausal Osteoporosis - Dormant Projects, 2022
Post Menopausal Osteoporosis - Dormant Projects, 2022 (Contd..1)
Post Menopausal Osteoporosis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Drugs In Development, 2022, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.
Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 20, 4, 10, 3, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis - Overview
Post Menopausal Osteoporosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Post Menopausal Osteoporosis - Drug Profiles
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT
Jun 17, 2022: Voluntary announcement - First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China
Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS
Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System
Dec 23, 2021: Radius announces update on TYMLOS (abaloparatide) label
Dec 08, 2021: Radius announces results from the wearABLe trial evaluating abaloparatide transdermal system in postmenopausal women with osteoporosis
Oct 06, 2021: Entera Bio presents positive phase 2 6-month bone mineral density data for oral PTH formulation at Late Breaker ASBMR Conference Session
Sep 22, 2021: Radius Health announces TYMLOS label and business update
Sep 01, 2021: Entera Bio selected for late breaking oral presentation of phase 2 6-month osteoporosis data at ASBMR 2021 Annual Meeting
Jan 25, 2021: Luye Pharma LY06006 completed the last dosing for all subjects in phase III Clinical in China
Dec 14, 2020: Samsung Bioepis initiates phase 3 clinical trial for SB16, proposed biosimilar to Prolia (Denosumab)
Oct 23, 2020: Boan Biotech receives EU clinical trials application approval for Denosumab injection
Sep 09, 2020: Radius Health announces scientific presentations on abaloparatide at ASBMR 2020 Annual Meeting
Sep 08, 2020: Radius Health: Enrollment completed for Phase 3 wearABLe trial
Aug 20, 2020: Entera Bio announces interim data from phase 2 clinical trial of EB613 in osteoporosis and second quarter 2020 financial results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Post Menopausal Osteoporosis - Dormant Projects, 2022
Post Menopausal Osteoporosis - Dormant Projects, 2022 (Contd..1)
Post Menopausal Osteoporosis - Discontinued Products, 2022
List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Related Report
